MGAT3 and neoplasm: MGAT3 modified N-glycosylation of epithelial growth factor receptor (EGFR) and integrin, and inhibited cell surface binding of EGFR/ integrin to galectin-3, resulting in their endocytosis, suppression of intracellular signaling, and consequent promotion of cell migration and tumor metastasis (Partridge et al., 2004).